Objective: Over 2 million American women at elevated risk for breast cancer are eligible to take chemoprevention medications such as tamoxifen and raloxifene, which can cut in half the risk of developing breast cancer, but which also have a number of side effects. Historically, very few at-risk women have opted to use chemoprevention medications. Affective forecasting theory suggests that people may avoid these medications if they expect taking them to increase their health-related stress. Method: After receiving an individually tailored decision aid that provided personalized information about the risks and benefits of these medications, 661 women at elevated risk of breast cancer were asked to make 3 affective forecasts, predicting what their level of health-related stress would be if they took tamoxifen, raloxifene, or neither medication. They also completed measures of decisional preferences and intentions, and at a 3-month follow-up, reported on whether or not they had decided to use either medication. Results: On the affective forecasting items, very few women (Ͻ10%) expected the medications to reduce their health-related stress, relative to no medication at all. Participants with more negative affective forecasts about taking a chemoprevention medication expressed lower preferences and intentions for using the medications (Cohen's ds from 0.74 to 0.79) and were more likely to have opted against using medication at follow-up (OR range ϭ 1.34 -2.66). Conclusion: These findings suggest that affective forecasting may explain avoidance of breast-cancer chemoprevention medications. They also highlight the need for more research aimed at integrating emotional content into decision aids.
Each year, over 1.5 million women worldwide are diagnosed with breast cancer, and over 500,000 die from the disease (Stewart & Wild, 2014) . Women at elevated risk have the option of taking a chemoprevention medication, such as tamoxifen or raloxifene, which can reduce the 5-year risk of developing breast cancer by about 50% (Nelson, Smith, Griffin, & Fu, 2013) . Based on a systematic literature review of randomized controlled trials and meta-analyses, the American Society for Clinical Oncology (Visvanathan et al., 2013) began advocating in 2013 that chemoprevention medications "should be discussed" by physicians and at-risk women. Also recognizing this evidence, the U.S. Preventive Services Task Force has given tamoxifen and raloxifene "Grade B" recommendations since 2013, meaning there is moderate-tohigh certainty of at least moderate benefit of these medications for at-risk women, and eligible patients should be engaged in a shared decision-making process with their physicians (Moyer, 2013) . Although over two million American women with elevated risk are eligible to take chemoprevention medications (Freedman et al., 2003) , few choose to do so, even when provided with information of the risks and benefits (Fagerlin et al., 2011) . Theories of decision making (Halpern & Arnold, 2008; Rhodes & Strain, 2008) suggest that health-care decisions are often driven by emotional processes such as "affective forecasting," which refers to people's expectations about the impact of their life choices on emotional well-being. For example, an individual might opt for a chemoprevention medication if she expects it to reduce her stress about developing cancer, but opt against medication if she believes it will increase her overall stress. In this study, we investigated at-risk women's affective forecasts to examine the extent to which they believe initiating a chemoprevention medication would increase or decrease their health-related stress, and whether these affective forecasts explained decision making about these medications.
In making health-care decisions about chemoprevention, emotional concerns are the proverbial elephant in the room, as the term "cancer" is inherently emotionally laden. Decision making about chemoprevention medications can be particularly emotionally burdensome given tradeoffs between the benefits and risks of such medications. Women with an elevated risk of developing breast cancer can be identified through self-report screening procedures (Amir, Freedman, Seruga, & Evans, 2010; Gail et al., 1989 ) that take no more than a few minutes and have evidence of high reliability and validity. For women identified as at-risk (e.g., Ն1.66% 5-year risk; Amir et al., 2010; Gail et al., 1989) , the decision to initiate a chemoprevention medication can be challenging because these medications reduce the risk of developing breast cancer (and bone fractures) but also increase the risk of side effects, such as cataracts, hormonal symptoms, sexual problems, deep vein thrombosis, pulmonary embolism, stroke, and endometrial cancer (Visvanathan et al., 2013) . Severe side effects are rare (e.g., among women ages 50 and over on tamoxifen, the 5-year absolute risk of stroke increases by 0.5% and risk of invasive endometrial cancer increases by 0.2%; Fisher et al., 1998) , though less serious side effects are more common (e.g., 12% absolute increase in the presence of hot flashes). These concerns about medication-specific physical side effects may compound more general concerns that taking any new medication would be stressful due to the hassle of taking a daily pill, in this case for a minimum of 5 years, as well as increased attention to health and mortality and other factors (Goldenberg & Arndt, 2008; Ropka, Keim, & Philbrick, 2010; Waters, Weinstein, Colditz, & Emmons, 2009 , Waters, Cronin, Graubard, Han, & Freedman, 2010 Zeber et al., 2013) .
Ultimately, few women choose to take a breast-cancer prevention medication (Visvanathan et al., 2013; Waters et al., 2010) . Only 0.08% of American women ages 40 and over have used one of these medications for chemoprevention, and in studies where at-risk women are informed of the risks and benefits, as little as 1% opt for medication (Fagerlin et al., 2011; Waters et al., 2010) . There have been calls for more research aimed at understanding the emotional processes that drive health-care decision making (see Nelson, Stefanek, Peters, & McCaul, 2005 , and other articles in that special issue; Elwyn, Stiel, Durand, & Boivin, 2011; Reyna, Nelson, Han, & Pignone, 2015; Sweeny, 2008) and it has been suggested that the side-effect profile of these medications, coupled with more general concerns about the emotional impact of taking a medication, might shape affective forecasts that drive medication avoidance. Specifically, people might avoid chemoprevention medications due to expectations that medication will increase, rather than decrease, their overall level of health-related stress (Waters et al., 2009 (Waters et al., , 2010 .
Outside of the breast-cancer prevention literature, a rapidly growing body of research on affective forecasting indicates that people routinely make life decisions based on their expectations about how their choices will impact later emotional well-being (e.g., work, personal finance, relationships, education, and leisure; see Wilson & Gilbert, 2013) . While health-care decision making in older populations is a significant and growing public health concern , a central limitation of the affective forecasting literature is that the vast majority of the more than 100 studies conducted in this area have involved student samples of young adults who were not facing health decisions (see Mathieu & Gosling, 2012; Wilson & Gilbert, 2013) . A few exceptions stand out. For example, affective forecasting has been linked to decisions about diet (Walsh & Kiviniemi, 2014) , exercise (Ruby, Dunn, Perrino, Gillis, & Viel, 2011) , vaccines (Chapman & Coups, 2006) , and colorectal cancer screening (Dillard, Fagerlin, Dal Cin, Zikmund-Fisher, & Ubel, 2010) , such that people engage in proactive health behaviors if they believe doing so will reduce stress, but avoid health behaviors if they believe engaging in them will increase stress. Affective forecasting might similarly influence decisions about chemoprevention medications.
The problem is that affective forecasts provide only a rudimentary window into the future, so they can leave people vulnerable to making imperfect decisions. Scores of studies have evaluated the accuracy of affective forecasting by systematically comparing people's predicted emotional reactions to events with their actual emotional reactions (see Mathieu & Gosling, 2012; Wilson & Gilbert, 2013) . That research has shown that affective forecasts are often prone to a number of errors and biases that can lead people to make decisions that are suboptimal, contrary to personal preferences, or later evoke regret (Dunn, Gilbert, & Wilson, 2011; Gilbert & Ebert, 2002; Kermer, Driver-Linn, Wilson, & Gilbert, 2006; Nisbet & Zelenski, 2011; though see also, Hoerger, Chapman, & Duberstein, 2015) . That body of research suggests that when imagining stressful scenarios-perhaps including initiating a medication with the potential for side effects-people's affective forecasts tend to be negatively biased (Wilson & Gilbert, 2013) due to underlying cognitive biases that lead people to focus on the most stressful aspect of the situation (Hoerger, Quirk, Lucas, & Carr, 2010; Kahneman, Krueger, Schkade, Schwarz, & Stone, 2006; Wilson, Wheatley, Meyers, Gilbert, & Axsom, 2000) , underestimate their coping skills (Gilbert, Pinel, Wilson, Blumberg, & Wheatley, 1998; Hoerger, 2012; Hoerger, Quirk, Lucas, & Carr, 2009) , and let the stress of the moment color perceptions of the future (Hoerger, Quirk, Chapman, & Duberstein, 2012; Wenze, Gunthert, & German, 2012) .
In a longitudinal study of women at high risk for breast cancer, we examined whether decision making about chemoprevention medications was explained by affective forecasting about healthrelated stress. The study involved primary analyses of existing data from the Guide to Decide study (Fagerlin et al., 2011) , which provided women with a tailored Web-based decision aid characterizing the medical risks and benefits of tamoxifen and raloxifene. The primary goal of the parent study was to examine the impact of risk-communication strategies on chemoprevention decision making. The current investigation is unique from some earlier investigations (e.g., Dillard et al., 2013; Zikmund-Fisher et al., 2008) , which focused solely on tamoxifen and did not examine affective forecasting. In the present study, our first goal was to test whether participants' affective forecasts reflected a belief that chemoprevention medication would increase, decrease, or have no effect on health-related stress, relative to taking no medication. Second, we examined whether affective forecasts of increased stress accounted for decisional preferences and intentions to avoid medication. Third, we examined whether affective forecasts predicted decisions to opt out against using a medication at 3-month follow-up and whether that relationship was explained by decisional preferences and intentions. To our knowledge, this is the first study seeking to apply basic research on affective forecasting toward This document is copyrighted by the American Psychological Association or one of its allied publishers.
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understanding medication decision making in breast-cancer prevention.
Method Procedures
Participants were women at elevated risk for developing breast cancer who were recruited from two U.S. health organizations: Group Health in Seattle, Washington and the Henry Ford Health System in Detroit, Michigan. Inclusion criteria included having an elevated risk of breast cancer, being 40 -74 years of age (i.e., ages approved for breast-cancer chemoprevention medications), and being postmenopausal (raloxifene has not been studied in premenopausal women). An elevated risk of breast cancer was defined as Ն1.66% chance of developing breast cancer during the next 5 years (the recommended minimum) as determined by the U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT, Amir et al., 2010) , which calculates risk based on the participant's age, race/ ethnicity, breast-cancer history, age of first live birth, age of first menses, history of breast biopsies, and the number of first-degree relatives with histories of breast cancer, using the Gail model (Amir et al., 2010; Gail et al., 1989) . Women were excluded if they were premenopausal (as they would not be eligible to take raloxifene), had a history of breast cancer or breast-cancer chemoprevention medication use, were pregnant or nursing, had contraindications to either medication, or had a terminal illness. Participants were not required to be aware of their elevated risk of breast cancer before enrolling in the study. Internal review board approval for this research was obtained from the Group Health Research Institute, Henry Ford Health System, and the University of Michigan. An automated electronic healthrecord review was used to identify potentially eligible women (N ϭ 14,048), namely those whose health records suggested they were at elevated risk. These women were then mailed letters inviting them to participate in an Internet study described as examining how health information can help women to make decisions about breast-cancer prevention. Of those contacted, 2,340 accessed the study site, where they completed an online consent form, followed by an eligibility screener assessing each of the inclusion and exclusion criteria.
Of the potential participants accessing the study web site, 1,012 were eligible, consented, and participated in the study. The analyses reported here involved participants randomized to the intervention arm (n ϭ 661) who completed a battery of survey measures following receipt of an Internet decision aid that provided personalized information about the risks and benefits of breastcancer chemoprevention medications; 322 controls did not receive tailored risk information; and 29 (3%) intervention participants were missing survey data. Analyses also examined responses from a subset of participants who completed a brief 3-month follow-up survey enquiring about their medication decision making. Participants received $10 gift cards for participating in the study.
The decision aid provided a combination of general and tailored information about breast cancer. General information included background information on breast cancer, a description of how breast-cancer chemoprevention medications work, an overview of the research used to study each drug, and information on potential benefits and risks of medication. The tailored information included providing each participant with individualized information about their 5-year risk of developing breast cancer based on their BCRAT score from the screener, as well as tailored information about the impact of raloxifene and tamoxifen on their risk of breast cancer, as well as their risk of side effects (tailored on age and race). Side effects described were hormonal symptoms, sexual problems, blood clots, cataracts, and endometrial cancer. The tailored risk information was repeated throughout the decision aid. All materials were written at an 8th-grade reading level.
Participants
Participant characteristics of the 661 women completing baseline measures are shown in Table 1 . The sample ranged in age from 46 to 74 and had BCRAT scores (representing risk of developing breast cancer in the next 5 years), ranging from 1.70 - 
Measures
Affective forecasting. Affective forecasting was operationalized as the predicted change in health-related stress if a participant decided to take a chemoprevention medication, as opposed to deciding not to take medication. Following the decision aid, participants completed three items. These assessed forecasts for taking tamoxifen (i.e., "Imagine that you do take tamoxifen. How worried would you be about getting any of the above health conditions?"), raloxifene ("Imagine that you do take raloxifene. How worried would you be about getting any of the above health conditions?"), and no medication ("Imagine that you do not take a breast-cancer prevention medication. How worried would you be about getting any of the above health conditions?"). The "above health conditions" referred to cancer and the medication side effects summarized above the questions. Each forecast was made on a scale from 1 (Not at all worried) to 6 (Extremely worried). Forecasts for tamoxifen and raloxifene were highly correlated, r ϭ .76, p Ͻ .001 and showed the same pattern of findings, so they were averaged (Cronbach's ␣ ϭ .86), and then we subtracted ratings for the nomedication scenario to provide a difference score reflecting expected change in health-related stress on medication relative to off medication: affective forecasting score ϭ (tamoxifen forecast ϩ raloxifene forecast)/2 -no-medication forecast. Positive scores indicated more forecasted worry on medication, and negative scores indicated less forecasted worry on medication. Comparable methods of assessment are used across the affective forecasting literature (e.g., Chapman & Coups, 2006; Mathieu & Gosling, 2012) .
Decisional preferences and intentions. Participants rated their preference for taking chemoprevention by responding to the question, "How good of a choice is taking a breast-cancer prevention drug as a way to reduce your chance of getting breast cancer?" using a 5-point rating scale (1 ϭ not a good choice at all, 5 ϭ extremely good choice), with higher values indicating greater preference. For behavioral intentions, participants responded to three items (e.g., "Given what you know right now, how likely do you think you are to . . . take a breast-cancer prevention drug?") assessing their intentions of talking to their doctor, looking up more information, and taking the medication; ratings were made on a 5-point scale (1 ϭ not at all likely, 5 ϭ extremely likely) , with higher scores indicating greater behavioral intentions (Cronbach's ␣ ϭ .85).
Decision making at follow-up. To assess the status of participants' decision making at the 3-month follow-up, they were asked, "Have you made a decision about whether or not to take a breast-cancer prevention drug?" Response options included (A) "Currently taking tamoxifen," (B) "Currently taking raloxifene," (C) "Still weighing whether to take a breast-cancer prevention drug," and (D) "Decided against taking a breast-cancer prevention drug."
Covariates. Age, numeracy, breast-cancer risk (BCRAT score), perceived risk of breast cancer, breast-cancer anxiety, and concerns about side effects were included as covariates. Numeracy was measured with the 8-item (Cronbach's ␣ ϭ .83) Subjective Numeracy Scale (Fagerlin et al., 2007) , which used a 6-point rating scale. For perceived risk of breast cancer, participants responded to the question using a 7-point rating scale:"Compared to the average woman your age, what are your chances of developing breast cancer in the next 5 years?" Participants completed a 4-item (Cronbach's ␣ ϭ .68) measure of breast-cancer anxiety (e.g., "I am worried about developing breast cancer in the next 5 years"), which used a 5-point rating scale. Concerns about side effects were assessed with an open-ended question asking what their main reason would be for not taking a breast-cancer prevention drug. Three raters, including a clinical psychologist (first author), a clinical psychology doctoral-level student, and an undergraduate, independently coded each response (Mdn ϭ 26 words) for the presence or absence of concerns about side effects; coding demonstrated excellent interrater reliability, namely a raw percent agreement of 94% and an intraclass correlation coefficient (ICC; analogous to a for Ͼ2 raters) of .96, with any inconsistencies resolved by consensus.
Analyses
Descriptive analyses were used to summarize ratings on each of the three affective forecasting items, and related to our first goal, a within-subject t test was used to compare whether participants' affective forecasts for taking a chemoprevention medication differed from their affective forecasts for not taking a medication. The remaining analyses focused on the affective forecasting difference score (i.e., average predicted stress on medication -predicted stress not on medication).
Related to our second goal, we examined whether affective forecasting was associated with medication preferences and intentions using zero-order correlations as well as regression analyses that controlled for covariates (i.e., age, numeracy, breast-cancer risk, perceived risk, breast-cancer anxiety, and concerns about side effects). To facilitate meaningful interpretation of these findings, we also conducted supplemental analyses using analysis of covariance (ANCOVA) to examine whether a dichotomous indicator of affective forecasting (0 ϭ expectations of no change or increased stress on medication, 1 ϭ expectations of reduced stress on medication) was associated with preferences and intentions while controlling for covariates. Cohen's d, the standardized mean difference, was used as an indicator of effect size (Cohen, 1988) .
Related to our third goal, we examined whether affective forecasting was associated with decisions made at follow-up. At the 3-month follow-up, only two participants had already initiated a chemoprevention medication (Responses A and B), so these categories were merged with the considering medication category (Response C) to yield a dichotomous decision variable (0 ϭ taking or considering medication, 1 ϭ decided against medication). Binary logistic regression was used to examine whether affective forecasting (continuous difference score) and the covariates were associated with decision making at follow-up. To facilitate meaningful interpretation of these findings, we also repeated analyses using the dichotomous indicator of affective forecasting, which allowed for straightforward comparisons of whether having favorThis document is copyrighted by the American Psychological Association or one of its allied publishers.
able versus neutral/negative affective forecasts about medication were associated with the odds of opting out against medication. Finally, we tested a mediational model to examine whether behavioral preferences and intentions mediated the relationship between affective forecasting and reports of decision making at follow-up. To simplify interpretation, the two indicators of preferences and intentions were combined into a single mediator using principal axis factoring. Mediation analyses controlled for the effects of the covariates on decisions made. As mediation with a dichotomous outcome variable requires transforming all unstandardized beta weights to a common metric, the Herr (2013) method was used to determine the proportion of the total effect explained by the mediator. As there are several methods for evaluating the statistical significance of an indirect effect, both the Sobel (1982) test and the Preacher and Hayes (2008) bias-corrected bootstrapping method were used.
Results

Affective Forecasting
On the affective forecasting questions, participants predicted that their health-related stress would average M ϭ 3.05 (SD ϭ 1.12) on the 1-6 rating scale if they took a breast-cancer prevention medication: tamoxifen, M ϭ 3.15 (SD ϭ 1.20); raloxifene, M ϭ 2.95 (SD ϭ 1.19), relative to predicted health-related stress, M ϭ 2.25 (SD ϭ 0.98) if they opted against medication. The raw difference between predicted stress on medication versus not on medication (affective forecasting difference score) was thus 0.80 raw points, which, if they opted for medication, was equivalent to a d ϭ 0.81 SD unit increase in forecasted health-related stress, t(660) ϭ 18.31, p Ͻ .001. The predicted level of change varied considerably across participants, ranging from Ϫ3 (anticipated lower stress on medication) to ϩ5 (anticipated higher stress on medication). As summarized in Figure 1 , less than 10% of participants (n ϭ 57) believed that taking a chemoprevention medication would reduce their health-related stress.
Decision Preferences and Intentions
Cross-sectional analyses supported the hypothesized relationship between affective forecasting and participants' preferences and behavioral intentions for using a breast-cancer chemoprevention medication. Affective forecasts of increased health-related stress on a chemoprevention medication were correlated with lower preferences, r ϭ Ϫ.24, p Ͻ .001 and intentions, r ϭ Ϫ.23, p Ͻ .001 for use of medication. As shown in the hierarchical regression analyses in Table 2 , affective forecasting continued to explain preferences (p Ͻ .001) and intentions (p Ͻ .001) when covariates were controlled for, meaning that these findings could not be attributed to confounding effects of age, numeracy, breastcancer anxiety, breast-cancer risk, perceived risk, or concerns about side effects. Similarly, in ANCOVA analyses examining affective forecasting categorically, preferences, d ϭ 0.74, F(1, 653) ϭ 27.90, p Ͻ .001 and intentions, d ϭ 0.79, F(1, 653) ϭ 31.46, p Ͻ .001, for use of medication were higher among participants with favorable affective forecasts about taking medication, preferences, M ϭ 2.59, SD ϭ 0.94; intentions, M ϭ 2.85 (SD ϭ 0.97) than among participants expecting no change or increased health-related stress on medication, preferences, M ϭ 1.90 (SD ϭ 0.93); intentions, M ϭ 2.09 (SD ϭ 0.95).
Decision Making at 3-Month Follow-Up
At the 3-month follow-up, 54.9% (n ϭ 202) of participants had decided against taking a chemoprevention medication. Only 0.5% (n ϭ 2) had initiated a chemoprevention medication (solely raloxifene), though 44.6% (n ϭ 164) were still weighing doing so; we merged these latter two groups together in subsequent analyses. As hypothesized, logistic regression analyses showed that affective forecasting was associated with medication decision making at the 3-month follow-up, including when covariates were controlled for (see Table 3 ), odds ratio ϭ 1.34, p ϭ .008. In further logistic regression analyses, examining affective forecasting categorically, the percentage of participants opting against medication at follow-up was lower among participants with favorable affective forecasts about taking medication (29.0%) than among participants expecting no change or increased health-related stress on medication (57.3%), OR ϭ 2.66, p ϭ .02, again while controlling for covariates. Thus, affective forecasting was uniquely predictive of subsequent medication decision making.
Mediation Analyses
The proposed mediational model was supported (see Figure 2) . In mediation analyses using the Herr (2013) This document is copyrighted by the American Psychological Association or one of its allied publishers.
relationship between affective forecasting and medication decision making at the 3-month follow-up (i.e., an unstandardized beta of .18 without controlling for behavioral preferences and intentions, changing to .07 after controlling for them, leading to a (.18 -.07)/ .18 ϭ .61 reduction in the coefficient representing the association between affective forecasting and the medication decision). The indirect effect was statistically significant using the Sobel test, z ϭ 4.59, p Ͻ .001, as well as the bias-corrected bootstrapping method, t(358) ϭ 3.36, p Ͻ .001. In summary, affective forecasting was predictive of participants' decision making about chemoprevention medications at the 3-month follow-up, with much of the relationship explained by the behavioral preferences and intentions that we assessed.
Discussion
In a large sample of women at elevated risk for developing breast cancer, the present investigation found that affective forecasting was associated with decision making about breast-cancer chemoprevention medications. Previous studies have called attention to the fact that few women opt to use breast-cancer chemoprevention medications (see Fagerlin et al., 2011; Waters et al., 2009 Waters et al., , 2010 . In the present investigation, participants received an individually tailored decision aid on the risks and benefits of chemoprevention medications. As hypothesized, when asked to forecast the impact of medication on their lives, few participants (Ͻ10%) reported believing that initiating a chemoprevention medication would reduce their health-related stress, and most thought medication would increase their stress (see Figure 1) . Also as hypothesized, those with more favorable affective forecasts about taking chemoprevention medications had stronger intentions and preferences for medication cross-sectionally and were less likely to have opted against using a medication at the 3-month follow-up. As well, the hypothesized mediational model was supported (see Figure 2) , with preferences and intentions explaining 61% of the relationship between affective forecasting and decision making at follow-up. Findings have implications for future research aimed at reducing cancer morbidity and mortality by understanding healthrelated decision making.
The present investigation extends a broader body of research and theory on the importance of affective forecasting in decision making. Basic research in this arena has shown that affective forecasting fuels decision making in many life domains (Mathieu & Gosling, 2012; Wilson & Gilbert, 2013 ), but few of those This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
studies have examined health-care decisions in older populations, despite growing public health significance (Halpern & Arnold, 2008; Rhodes & Strain, 2008; Zikmund-Fisher et al., 2010) . As the pipeline from basic research discoveries toward public health solutions has historically moved slowly (Berwick, 2003) , there have been calls for translational research to bridge that gap (Woolf, 2008) . A few studies have shown the importance of affective forecasting for other health-promotion behaviors (Chapman & Coups, 2006; Dillard et al., 2010; Ruby et al., 2011; Walsh & Kiviniemi, 2014) , and this is the first investigation of which we are aware to show that affective forecasting is related to medication decision making, and more specifically, related to decision making about breast-cancer chemoprevention. Thus, these findings contribute to understanding the emotional pathways that may influence decision making in cancer prevention. Our research also raises the question of why participants' affective forecasts about taking chemoprevention medications were so negative (see Figure 1) . One possibility is that the women are accurate in their forecasts about taking a chemoprevention medication, in that it would increase their health-related stress. However, high-powered randomized controlled trials have repeatedly failed to find evidence of exacerbated stress in at-risk women taking chemoprevention medications (Day et al., 1999 , Day, Ganz, & Costantino, 2001 Fisher et al., 1998; Land et al., 2006) . Alternatively, it is possible that participants' affective forecasts about taking chemoprevention medications may have been negatively biased. Affective forecasting research has identified three cognitive biases that can routinely lead people to have unduly negative perceptions of stressful scenarios, like initiating a new medication (for a review, see Wilson & Gilbert, 2013) . One, people tend to focus on the most stressful aspect of a situation (a bias called focalism, Hoerger et al., 2010; Kahneman et al., 2006; Wilson et al., 2000) , which might involve focusing disproportionately on the possibility of side effects or other concerns. Two, people underestimate their resilience in coping with stressful scenarios (variously called immune neglect, adaptation neglect, or coping fallacy; Gilbert et al., 1998; Hoerger, 2012; Hoerger et al., 2009 ), meaning they might adjust to taking a medication more easily than imagined. Three, stress in the moment, including perhaps learning new risk information through a decision aid, may lead people to overestimate future stress (dysphoric forecasting bias; Hoerger, Quirk et al., 2012; Wenze et al., 2012) . Our research has shown that affective forecasting about chemoprevention medications is negative, and more research appears warranted to begin to determine whether these expectations are relatively realistic versus negatively biased, for whom, and under what circumstances.
Multivariate analyses showed, when we controlled for key covariates, that affective forecasting uniquely accounted for decision making (see Tables 2 and 3) . Prior research has suggested that older age, greater risk and perceived risk, numeracy, breast-cancer anxiety, and fewer concerns about side effects may increase preferences for chemoprevention medications (Bober, Hoke, Duda, Regan, & Tung, 2004; Dillard et al., 2013; Zikmund-Fisher et al., 2008) . We found no effect of age or numeracy in the present analyses. Breast-cancer risk, perceived risk, and lower concerns about side effects were associated with greater preferences and intentions cross-sectionally but did not predict decision making at the 3-month follow-up. Breast-cancer anxiety was associated with greater preferences and intentions, as well as a reduced likelihood of opting against chemoprevention medications at follow-up. The central focus of these analyses was affective forecasting, but breast-cancer anxiety and affective forecasting each uniquely ac-
Affective Forecasting
Belief that chemoprevention medication would increase healthrelated stress Affective forecasting that chemoprevention medications would increase health-related stress was associated with a greater likelihood of opting out against medication at follow-up. Behavioral preferences and intentions were found to explain the relationship between affective forecasting and medication decision making. Each coefficient is an unstandardized beta (B) transformed to a common metric. The indirect effect was statistically significant, p Ͻ .001. Analyses controlled for the covariates of age, numeracy, breast-cancer risk, perceived risk, breastcancer anxiety, and concerns about side effects. N ϭ 368.
Medication
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counted for decision making. Both findings point to the need for more research examining emotional processes implicated in cancer prevention. The present investigation had several notable strengths, but findings were also tempered by several limitations. Strengths included the relatively novel application of affective forecasting theory toward understanding health-care decision making, the use of a decision aid that was tailored with personalized risk information, and the implementation of extensive screening processes (i.e., medical record reviews, mailings, and Internet-mediated cancerrisk screenings) needed to obtain data from a large sample of women at elevated risk of breast cancer. However, a key limitation was that the majority of participants were white and collegeeducated, and follow-up studies would be useful for gauging the extent to which the same emotional processes shape decision making in samples that are more racially and ethnically diverse or have less educational training. As well, all findings were correlational, and follow-up studies piloting interventions aimed at modifying affective forecasts would support stronger causal inferences. Finally, at the 3-month follow-up, only 0.5% of participants had initiated a chemoprevention medication, with many still weighing their decision and over half having explicitly decided against medication. Thus, the present findings speak more to factors underlying medication avoidance than those sparking medication initiation, and they suggest that future investigators should consider longer follow-up phases to allow more time for decision making to solidify.
The current study has implications for future research aimed at reducing the toll of breast cancer. Affective forecasting about breast-cancer chemoprevention medications was negative, and future studies should aim to understand whether these forecasts are realistic or biased. An ideal study might compare at-risk women's predicted versus actual emotional reactions to chemoprevention medications, but such a study would be difficult to implement, given that so few women actually agree to use the medications. Alternatively, several studies have examined interventions used to improve affective forecasting accuracy (e.g., Gilbert, Killingsworth, Eyre, & Wilson, 2009; Hoerger et al., 2009 Hoerger et al., , 2010 , and future studies could examine whether affective forecasting interventions adapted for this context augment preferences for chemoprevention medications.
Historically, medical encounters and decision aids have often provided extensive health information, risk statistics, and graphs, but this information is often insufficient for increasing uptake of chemoprevention medications Melnikow et al., 2005; Port, Montgomery, Heerdt, & Borgen, 2001; Stacey, O'Connor, De Grasse, & Verma, 2003) . It may be useful to integrate more content addressing emotional concerns into decision interventions (Elwyn et al., 2011; Hoerger et al., 2013) , particularly given that people's emotional, gist-level understanding of the situation (e.g., "the medication sounds scary") is increasingly thought to affect health-care decision making (Reyna, 2008; Reyna et al., 2015; Slovic, Peters, Finucane, & MacGregor, 2005 ). An important next step would be to study factors underlying unfavorable affective forecasts about medication to address them directly in decision aids. Our affective forecasting questions queried global health-related stress regarding taking versus not taking a chemoprevention medication, and future studies could explore more specific questions, such as forecasts about the expected stress of particular physical side effects, attending more closely to one's health, managing a medication regimen, or other factors. Integrating emotional content into decision aids is a challenging feat (Waters, Weinstein, Colditz, & Emmons, 2007) , though nonstatistical methods, such as narrative video-based content may help (Katz et al., 2009) . Providing individuals with information on normative emotional reactions to life events has been shown to improve affective forecasting (Gilbert et al., 2009 ); thus, it could be useful for decision aids to describe typical stress levels experienced by actual patients on chemoprevention medications, including global health-related stress as well as stress regarding key concerns, such as side effects. In the wake of recent health-care reforms, a pressing national priority is to identify treatment outcomes that matter to patients, such as the stress experienced while taking a chemoprevention medication, and provide individuals with the requisite outcome data needed to make informed healthcare decisions (Hoerger, in press; Selby, Beal, & Frank, 2012) .
